^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CimaVax EGF (EGF-PTI)

    i
    Other names: EGF-PTI, BV-NSCLC-001, EGF-P64K, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
    Associations

    News

    Trials
    Company:
    CIMAB, In3Bio
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    24d
    CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=51, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=242 --> 51 | Trial primary completion date: Dec 2027 --> May 2025
    Enrollment closed • Enrollment change • Trial primary completion date • Pan tumor
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)
    1m
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=42 --> 2
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    7ms
    A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence (clinicaltrials.gov)
    P1, N=60, Recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Nov 2029 | Trial primary completion date: Nov 2025 --> Nov 2029
    Trial completion date • Trial primary completion date
    |
    CimaVax EGF (EGF-PTI)
    9ms
    CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=242, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension • IO biomarker • Pan tumor
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • EGFR mutation • EGFR expression • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)
    10ms
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=42, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    11ms
    A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence (clinicaltrials.gov)
    P1, N=60, Recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    CimaVax EGF (EGF-PTI)
    almost2years
    Safety and effectiveness of CIMAvax-EGF administered in community polyclinics. (PubMed, Front Oncol)
    We conclude that community polyclinics constitute the optimal scenario for administering those cancer vaccines that are safe and require prolonged maintenance in patients with advanced cancer, despite the continuous deterioration of their general condition. https://rpcec.sld.cu/trials/RPCEC00000205-En, identifier RPCEC00000205.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    CimaVax EGF (EGF-PTI)
    2years
    CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=242, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2027
    Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK mutation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)
    2years
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=42, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    over2years
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Roswell Park Cancer Institute
    New P1 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    over2years
    A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence (clinicaltrials.gov)
    P1, N=60, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    CimaVax EGF (EGF-PTI)